198 related items for PubMed ID: 17699247
1. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV, Holub BJ, Southwest Pediatric Nephrology Study Group.
Clin J Am Soc Nephrol; 2006 May; 1(3):467-74. PubMed ID: 17699247
[Abstract] [Full Text] [Related]
2. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[Abstract] [Full Text] [Related]
3. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP.
J Nephrol; 2001 May; 14(4):248-52. PubMed ID: 11506246
[Abstract] [Full Text] [Related]
4. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[Abstract] [Full Text] [Related]
5. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.
J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
[Abstract] [Full Text] [Related]
6. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study Group.
Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
[Abstract] [Full Text] [Related]
7. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study.
Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Björkhem I, Bergström J.
Clin Nephrol; 1994 Apr; 41(4):183-90. PubMed ID: 8026109
[Abstract] [Full Text] [Related]
8. ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.
Liu LL, Wang LN.
Clin Nephrol; 2012 Feb; 77(2):119-25. PubMed ID: 22257542
[Abstract] [Full Text] [Related]
9. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U, Ong-Ajyooth L, Parichatikanond P, Ong-Ajyooth S, Liammongkolkul S, Kanyog S.
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[Abstract] [Full Text] [Related]
10. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV, Bergstralh EJ, Bibus DM, Grande JP.
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[Abstract] [Full Text] [Related]
11. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy.
Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S.
N Engl J Med; 1989 Jan 26; 320(4):210-5. PubMed ID: 2643046
[Abstract] [Full Text] [Related]
12. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
Clin Ther; 2008 Mar 26; 30(3):482-98. PubMed ID: 18405787
[Abstract] [Full Text] [Related]
13. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group.
Clin J Am Soc Nephrol; 2006 May 26; 1(3):511-7. PubMed ID: 17699253
[Abstract] [Full Text] [Related]
14. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial.
Murphy BL, Stoll AL, Harris PQ, Ravichandran C, Babb SM, Carlezon WA, Cohen BM.
J Clin Psychopharmacol; 2012 Oct 26; 32(5):699-703. PubMed ID: 22926607
[Abstract] [Full Text] [Related]
15. Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials.
Chou HH, Chiou YY, Hung PH, Chiang PC, Wang ST.
Nephron Clin Pract; 2012 Oct 26; 121(1-2):c30-5. PubMed ID: 23095320
[Abstract] [Full Text] [Related]
16. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
Medicina (B Aires); 2007 Oct 26; 67(5):445-50. PubMed ID: 18051227
[Abstract] [Full Text] [Related]
17. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group.
Clin J Am Soc Nephrol; 2006 Nov 26; 1(6):1167-72. PubMed ID: 17699343
[Abstract] [Full Text] [Related]
18. [Treatment of IgA nephropathy with chronic renal failure].
Pozzi C.
G Ital Nefrol; 2008 Nov 26; 25 Suppl 44():83-7. PubMed ID: 19048591
[Abstract] [Full Text] [Related]
19. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
Am J Hypertens; 2007 Nov 26; 20(11):1195-201. PubMed ID: 17954367
[Abstract] [Full Text] [Related]
20. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
Am J Kidney Dis; 2009 Apr 26; 53(4):606-16. PubMed ID: 19216016
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
